Hologic (HOLX) Citi's 2024 Global Healthcare Conference summary

Product launches and innovation

• Launched next-generation Envision gantry at RSNA, focusing on image quality, workflow, and patient experience.

• Envision features reduced compression time, tilt functionality for better patient access, and improved image capture.

• Commercial availability for Envision expected in 2026, with a smooth transition planned due to backward compatibility.

• Software improvements included as standard, with ongoing enhancements to installed base.

Business segment performance and outlook

• Breast Health division expects low to mid-single-digit growth in 2025, with service contracts as the revenue foundation.

• Interventional business is a key growth driver, supported by the Endomag acquisition and direct sales integration in the U.S.

• Molecular Diagnostics growth led by BV, CV/TV assays, with further runway and international expansion potential.

• Biotheranostics acquisition adds specialty lab services, contributing over $100 million in revenue and early-stage market penetration.

Supply chain and operational updates

• Chip shortage and elevated costs are at the tail end, with manufacturing consolidation expected to benefit margins by late 2025.

• Backlog levels have normalized, returning to pre-pandemic operating processes.

• IV saline bag shortage impacted elective procedures, with recovery expected by end of calendar year or into Q2.